CSIMarket
 

Eli Lilly And Company  (LLY)
Other Ticker:  
 

Eli Lilly's

Competitiveness


 

LLY Sales vs. its Competitors Q3 2022



Comparing the results to its competitors, Eli Lilly reported Total Revenue increase in the 3 quarter 2022 by 2.49 % year on year.
The sales growth was above Eli Lilly's competitors average revenue growth of 1.93 %, recorded in the same quarter.

List of LLY Competitors

With net margin of 20.91 % company reported lower profitability than its competitors.

More on LLY Margin Comparisons



Revenue Growth Comparisons




Net Income Comparison


Eli Lilly And Company Net Income in the 3 quarter 2022 grew year on year by 30.77 %, while most of its competitors have experienced contraction in net income by -6.25 %.

<<  More on LLY Income Comparisons


Eli Lilly's Comment on Competitors and Industry Peers


Our human pharmaceutical products compete globally with products of many other companies in highly competitive markets. Our animal health products compete globally with products of animal health care companies as well as pharmaceutical, chemical, and other companies that operate animal health businesses.
Important competitive factors for both human pharmaceutical and animal health products include effectiveness, safety, and ease of use; price and demonstrated cost-effectiveness; marketing effectiveness; and research and development of new products and processes. Most new products that we introduce must compete with other branded or generic products already on the market or products that are later developed by competitors. If competitors introduce new products or delivery systems with therapeutic or cost advantages, our products can be subject to decreased sales, progressive price reductions, or both.

We believe our long-term competitive success depends upon discovering and developing (either alone or in collaboration with others) or acquiring innovative, cost-effective human pharmaceutical and animal health products that provide improved outcomes and deliver value to payers, together with our ability to continuously improve the productivity of our operations in a highly competitive environment. There can be no assurance that our research and development efforts will result in commercially successful products, and it is possible that our products will become uncompetitive from time to time as a result of products developed by our competitors.

Generic Pharmaceuticals
One of the biggest competitive challenges we face is from generic pharmaceuticals. In the U.S. and the EU, the regulatory approval process for human pharmaceuticals (other than biological products (biologics)) exempts generics from costly and time-consuming clinical trials to demonstrate their safety and efficacy, allowing generic manufacturers to rely on the safety and efficacy of the innovator product. Therefore, generic manufacturers generally invest far less than we do in research and development and can price their products much lower than our branded products. Accordingly, when a branded non-biologic human pharmaceutical loses its market exclusivity, it normally faces intense price competition from generic forms of the product. In many countries outside the U.S., intellectual property protection is weak and we must compete with generic or counterfeit versions of our products. Many of our animal health products also compete with generics.





  

Overall company Market Share Q3 2022

With modest revenue growth of 2.49 % within Overall company, Eli Lilly And Company managed to improve its market share within this segment to approximate 7.9 %.
<<  More on LLY Market Share.
 
*Market share is calculated based on total revenue.


LLY's vs. Competition, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)


COMPANY NAME MARKET CAP
(in millions of $)
REVENUES
(in millions of $)
INCOME
(in millions of $)
EMPLOYEES
Eli Lilly And Company LLY 336,619.32 29,240.00 6,033.00 33,625
Bristol myers Squibb Company BMY 170,664 46,738.00 6,692.00 30,250
Johnson and Johnson JNJ 470,624 95,245.00 19,139.00 132,200
Merck and Co Inc MRK 278,440 57,521.00 15,274.00 71,000
Mylan N v MYL 8,208 16,861.30 266.40 25,000
Pfizer Inc PFE 288,416 89,344.00 25,762.00 88,300
Abbott Laboratories ABT 185,228 45,030.00 7,889.00 107,000
Enact Holdings Inc ACT 3,897 -2,298.14 1,795.44 0
Amgen Inc AMGN 152,324 32,341.00 6,835.00 24,300
Procter and Gamble Co PG 375,490 80,461.00 14,630.00 99,000
Patterson Companies Inc PDCO 2,830 6,384.84 197.88 7,000
Petvivo Holdings Inc PETV 23 0.39 -7.50 4
Abbvie Inc ABBV 290,412 57,819.00 13,418.00 38,500
Gilead Sciences Inc GILD 110,779 27,136.00 3,309.00 11,800
Glaxosmithkline Plc GSK 192,008 34,114.00 5,096.00 0
SUBTOTAL 2,865,961.74 615,936.88 126,329.42 667,979
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

TONJ's Profile

Stock Price

TONJ's Financials

Business Description

Fundamentals

Charts & Quotes

TONJ's News

Suppliers

TONJ's Competitors

Customers & Markets

Economic Indicators

TONJ's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071